Detailed contribution information
| Contribution title | 2632 - Drug utilization patterns of lisdexamfetamine dimesylate in children, adolescents and adults in six European countries |
|---|---|
| Contribution code | PS02-65 (P) |
| Authors | |
| Form of presentation | Poster |
| Topic |
|
| Abstract |
Objectives Lisdexamfetamine dimesylate (LDX) is indicated for attention-deficit/hyperactivity disorder (ADHD) in children aged 6–17 years and, in some countries, in adults. There is, however, limited evidence on the real world use of LDX across Europe. As part of an ongoing, retrospective study into patterns of LDX prescriptions, we report LDX drug utilization patterns from six European countries for which robust data are currently available. Methods Demographic, clinical, and drug utilization data were collected from national registries (Denmark and Sweden), electronic medical records (Germany, Disease Analyzer; Spain, LPD; UK, CPRD) and prescription/cross-sectional databases (Spain, MIDAS PI; Switzerland, IFAK/New Index and SDI). Patients were included if prescribed LDX at least once between 4 March 2013 and 31 December 2014 (Denmark and Sweden) or 31 December 2015 (Germany, Spain, Switzerland, and UK). Results Patient numbers were as follows: 9,111 in Sweden, 3,433 in Denmark, 1,889 in Germany, 1,158 in Switzerland, 593 in the UK, and 273 in Spain. In all countries, most patients were male (60–81%). Less than 1% of patients were under 6 years of age. The proportions of patients receiving LDX who were adults (> 18 years old) were lower in Germany (4%), UK (13%), and Spain (14%), than in Denmark (42%), Switzerland (59%), and Sweden (60%). An ADHD diagnosis was documented in the patient’s history for 50–92% of patients (this information was not available in Switzerland). In patients with at least one year history, the proportions who received methylphenidate before their first documented LDX prescription ranged from 80% (Switzerland) to 97% (Spain). The proportion of patients who switched from other medications to LDX ranged from 23% (UK) to 79% (Spain). Data on the recommended dose was only recorded in Germany and the UK; the prescribed average daily dose (ADD) of LDX was less than or equal to 70 mg for over 99% of patients in both countries, with mean calculated ADD for these patients of 45 mg in Germany and 47 mg in the UK. Conclusions Based on these interim analyses of data from an ongoing study, LDX is mainly prescribed within the bounds of the Summary of Product Characteristics with regard to treatment history and dose regimen. There was a high proportion of off-label use of LDX in adults in Denmark and Sweden prior to 2015 when the adult indication was approved. Study funded by Shire Development LLC. |